Terry O Matsunaga, PharmD, PhD

tmatsunaga@radiology.arizona.edu

Links

Department Profile

NCBI Bibliography

Dr. Matsunaga received his AB degree in Biochemistry from the University of California at Berkeley, followed by a Pharm.D in Clinical Pharmacy at the University of California San Francisco (UCSF). Following a year of clinical training as a resident at the University of Michigan, he returned to UCSF where he received his Ph.D. in Pharmaceutical Chemistry under the mentorship of George L. Kenyon. From 1986 - 1992, he was a NIDA post-doctoral fellow in the laboratory of Professor Victor J. Hruby. Since 2010, he has chaired the Steering Committee for the NHLBI SMARTT (Science Moving Towards Research Translation and Therapy) Program.

Cancer Focus

Dr. Matsunaga studies contrast enhanced ultrasound (CEUS) with a focus on micro bubble development and phase-change per fluorocarbon contrast agents for vascular and extravascular imaging. His current research emphasizes the potential for early detection of breast cancer.

Research Program Role

Clinical and Translational Oncology Program

Display Name
Terry O Matsunaga, PharmD, PhD

Publications

Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells.

Hadinger KP, Marshalek JP, Sheeran PS, Dayton PA, Matsunaga TO. 2018. Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells. Ultrasound Med Biol. 44:2728–2738. doi:10.1016/j.ultrasmedbio.2018.08.003.

Imaging of targeted lipid microbubbles to detect cancer cells using third harmonic generation microscopy.

Harpel K, Baker RD, Amirsolaimani B, Mehravar S, Vagner J, Matsunaga TO, Banerjee B, Kieu K. 2016. Imaging of targeted lipid microbubbles to detect cancer cells using third harmonic generation microscopy. Biomed Opt Express. 7:2849–60. doi:10.1364/BOE.7.002849.

A novel small molecule inhibitor of the DNA repair protein Ku70/80.

Weterings E, Gallegos AC, Dominick LN, Cooke LS, Bartels TN, Vagner J, Matsunaga TO, Mahadevan D. 2016. A novel small molecule inhibitor of the DNA repair protein Ku70/80. DNA Repair (Amst). 43:98–106. doi:10.1016/j.dnarep.2016.03.014.

Intracellular delivery and ultrasonic activation of folate receptor-targeted phase-change contrast agents in breast cancer cells in vitro.

Marshalek JP, Sheeran PS, Ingram P, Dayton PA, Witte RS, Matsunaga TO. 2016. Intracellular delivery and ultrasonic activation of folate receptor-targeted phase-change contrast agents in breast cancer cells in vitro. J Control Release. 243:69–77. doi:10.1016/j.jconrel.2016.09.010.

Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound.

Sheeran PS, Luois S, Dayton PA, Matsunaga TO. 2011. Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound. Langmuir. 27:10412–20. doi:10.1021/la2013705.